Rohit Kumar Singh is an early-career finance professional and independent equity researcher with experience in financial data analysis and fundamental valuation. He works at S&P Global and has built a parallel body of equity research across Indian listed companies.
At S&P Global, he analyzes financial and non-financial documents to extract structured data for institutional clients, applying judgment when regulatory differences require mapping outside standard frameworks.
Independently, he has published equity research reports on Bharti Airtel, Zydus Lifesciences, and Laurus Labs, building full DCF models and forming independent buy and sell views. His Zydus report identified the company's transition from generic to innovative drug development as a structural re-rating catalyst. His Bharti Airtel analysis concluded the stock was pricing in 5G optionality beyond what his revenue and margin projections supported.
